TY - JOUR
T1 - Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
AU - Reck, Martin
AU - Garassino, Marina Chiara
AU - Imbimbo, Martina
AU - Shepherd, Frances A.
AU - Socinski, Mark A.
AU - Shih, Jin Yuan
AU - Tsao, Anne
AU - Lee, Pablo
AU - Winfree, Katherine B.
AU - Sashegyi, Andreas
AU - Cheng, Rebecca
AU - Varea, Rocio
AU - Levy, Benjamin
AU - Garon, Edward
N1 - Publisher Copyright:
© 2018
PY - 2018/6
Y1 - 2018/6
N2 - A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients. This review summarizes the approved antiangiogenic therapies for the treatment of patients with advanced NSCLC in the second-line setting, specifically focusing on the outcomes from subgroups of patients with rapidly progressing or refractory disease. Several antiangiogenic agents, as monotherapy or in combination with other treatments, have been or are currently being studied in patients with advanced NSCLC. Antiangiogenics that are approved for use in patients with advanced NSCLC are limited to bevacizumab in combination with chemotherapy (nonsquamous NSCLC), ramucirumab in combination with docetaxel (all histologies), and nintedanib in combination with docetaxel (adenocarcinoma histology). This review focuses on the efficacy, safety, and quality of life outcomes in the subpopulation of patients with rapidly progressing or refractory NSCLC treated with approved antiangiogenic therapies in the second-line setting. We also discuss the impact of newly approved immunotherapy agents on the outcomes of patients with aggressive or refractory disease. Studies in progress and planned future research will determine if combination treatment with antiangiogenics and immunotherapies will benefit patients with aggressive, advanced NSCLC.
AB - A majority of patients with advanced or metastatic non-small cell lung cancer (NSCLC) will experience disease progression after first-line therapy. Patients who have advanced NSCLC that is especially aggressive, which is defined as disease that rapidly progresses on first-line treatment or disease that is refractory to first-line treatment, have a critical unmet medical need. These patients have a poor prognosis in the second-line setting. Several studies have recently shown that treatment with an antiangiogenic therapy may benefit these patients. This review summarizes the approved antiangiogenic therapies for the treatment of patients with advanced NSCLC in the second-line setting, specifically focusing on the outcomes from subgroups of patients with rapidly progressing or refractory disease. Several antiangiogenic agents, as monotherapy or in combination with other treatments, have been or are currently being studied in patients with advanced NSCLC. Antiangiogenics that are approved for use in patients with advanced NSCLC are limited to bevacizumab in combination with chemotherapy (nonsquamous NSCLC), ramucirumab in combination with docetaxel (all histologies), and nintedanib in combination with docetaxel (adenocarcinoma histology). This review focuses on the efficacy, safety, and quality of life outcomes in the subpopulation of patients with rapidly progressing or refractory NSCLC treated with approved antiangiogenic therapies in the second-line setting. We also discuss the impact of newly approved immunotherapy agents on the outcomes of patients with aggressive or refractory disease. Studies in progress and planned future research will determine if combination treatment with antiangiogenics and immunotherapies will benefit patients with aggressive, advanced NSCLC.
KW - Angiogenesis
KW - Immunotherapy
KW - Nintedanib
KW - Non-small-cell lung cancer
KW - Ramucirumab
UR - http://www.scopus.com/inward/record.url?scp=85044959258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044959258&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2018.03.025
DO - 10.1016/j.lungcan.2018.03.025
M3 - Review article
C2 - 29748017
AN - SCOPUS:85044959258
SN - 0169-5002
VL - 120
SP - 62
EP - 69
JO - Lung Cancer
JF - Lung Cancer
ER -